Drug Interactions between cholera vaccine, live and teplizumab
This report displays the potential drug interactions for the following 2 drugs:
- cholera vaccine, live
- teplizumab
Interactions between your drugs
cholera vaccine, live teplizumab
Applies to: cholera vaccine, live and teplizumab
Consumer information for this interaction is not currently available.
ADJUST DOSING INTERVAL: The administration of live, attenuated viral or bacterial vaccines or oncolytic immunotherapy containing live, attenuated virus or bacteria to patients receiving teplizumab is not recommended, and may be associated with a risk of disseminated infection due to enhanced replication of virus or bacteria in the presence of diminished immune competence. In addition, teplizumab may interfere with the immune response to vaccination and decrease vaccine efficacy. However, data are not available. A specific timeframe for immunization of infants exposed to teplizumab in utero is not available due to a lack of sufficient data about infant serum levels or the duration of persistence of teplizumab in infant serum after birth.
MANAGEMENT: The administration of live, attenuated viral or bacterial vaccines or oncolytic immunotherapy containing live, attenuated virus or bacteria is not recommended within the 8 weeks prior to treatment, during, and for up to 52 weeks after treatment with teplizumab. Patients should be advised to receive all age-appropriate vaccinations prior to starting treatment with teplizumab. The risks and benefits should be considered prior to the administration of live, attenuated viral or bacterial vaccines or oncolytic immunotherapy containing live, attenuated virus or bacteria to infants exposed to teplizumab in utero.
References
- (2022) "Product Information. Tzield (teplizumab)." Provention Bio, Inc.
Drug and food interactions
cholera vaccine, live food
Applies to: cholera vaccine, live
Consumer information for this interaction is not currently available.
ADJUST DOSING INTERVAL: Coadministration of oral cholera vaccine with food or an oral beverage may impair its efficacy. The formulations of both the inactivated and live, attenuated oral cholera vaccines (Dukoral and Vaxchora, respectively) are acid-labile, and must be administered with a buffer. According to the manufacturer, eating and drinking may interfere with the protective effect of the buffer. However, clinical data are not available.
MANAGEMENT: It is recommended that patients avoid eating or drinking for 60 minutes before and after administration of either Dukoral or Vaxchora oral cholera vaccines.
References
- (2023) "Product Information. Vaxchora (cholera vaccine, live)." Patientric Ltd
- (2022) "Product Information. Dukoral (vibrio cholerae vaccine)." Valneva Sweden AB
- (2023) "Product Information. Dukoral (cholera vaccine)." Valneva UK Ltd
- (2024) "Product Information. Vaxchora (cholera vaccine, live)." Emergent Travel Health, Inc
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Report options
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.
